Umbilical cord blood-derived cytotoxic T lymphocytes target melanoma via HLA-A2-restricted tumour antigens.

ABSTRACT:

Background

Melanoma is recognized as a highly malignant cancer with a generally poor prognosis, underscoring the critical need for effective therapeutic strategies. Adoptive cell therapy has emerged as a promising modality to improve treatment outcomes in melanoma. For endogenous cell therapy (ECT), peripheral blood (PB) has traditionally served as the primary cell source. However, the potential of umbilical cord blood (UCB) as an alternative source for ECT remains unclear. Furthermore, the repertoire of TCRs remains limited. These deficiencies impede the optimization and broader application of ECT for melanoma, highlighting the necessity for focused investigations to resolve these issues.

Methods

To evaluate the effects of HLA-A2 restricted antigen-specific CD8⁺ T cells on

SUBMITTER: Liang J 

PROVIDER: S-EPMC12521828 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature